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Abstract: First evidence of cases of haemophilia dates from ancient Egypt, but it was when
Queen Victoria from England in the 19th century transmitted this illness to her
descendants, when it became known as the "royal disease". Last decades of the 20th
century account for major discoveries that improved the life expectancy and quality of
life of these patients. The history and evolution of haemophilia healthcare counts ups
and downs. The introduction of prophylactic schemes during the 1970s have proved to
be more effective that the classic on- demand replacement of clotting factors,
nevertheless many patients managed with frequent plasma transfusions or derived
products became infected with the Human Immunodeficiency Virus (HIV) and Hepatitis
C virus during the 1980s and 1990s.  Recombinant factor VIII inception has decreased
the risk of blood borne infections and restored back longer life expectancies. Main
concerns for haemophilia healthcare are shifting from the pure clinical aspects to the
economic considerations of long term replacement therapy.  Nowadays researchers'
attention has been placed on the future costs and cost-effectiveness of costly long term
treatment.  Equity considerations are relevant as well, and alternative options for less
affluent countries are under the scope of further research. The aim of this review was
to assess the evidence of different treatment options for haemophilia type A over the
past four decades, focusing on the most important technological advances that have
influenced the natural course of this "royal disease".
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Introduction: 
Haemophilia accounts for a long historic pathway; some authors may argue the 
first case dates from ancient Egypt (1), others state the first registered reference 
comes from Hebrew texts from the II century A.D, these writings explicitly banned 
circumcision for those children with a previous family history of at least two 
deceased brothers due to haemorrhage after this procedure. In the 19th Century 
Haemophilia became popular when Queen Victoria from England “transmitted” the 
haemophilia A genetic inheritance to several royal houses in Europe, including her 
latest son Leopold who died at the age of 30, after a bleeding episode due to a 
mild knee trauma; by that time haemophilia became known as the "royal 
disease"(2).  
It is estimated that 1 per 5000- 10.000 male births is going to suffer haemophilia A. 
(3,4) Debuting age, location and severity of bleeding depend on the activity level of 
clotting factor VIII. Clinical categories of haemophilia are: patients with mild 
deficiency (5 - 40% activity of factor VIII (FVIII)), usually tend to bleed only after 
major surgical procedures, patients with moderate deficiency (1 - 5% activity of 
FVIII) and severe (< 1% activity) usually become symptomatic after minor surgical 
procedures or spontaneously. Around 70 - 80% of bleeding episodes affect the 
joints leading to haemarthrosis and progressive haemophilic arthropathy as the 
most important long time complication (3, 4).  
The clinical spectrum of severe haemophilia has evolved throughout history from 
being a catastrophic and highly fatal condition in the early 20th century to a chronic 
and “manageable” disorder in recent decades. In 1940 the first successful medical 
treatment for haemophilia was published in the Lancet, an 11 years old boy that 
experienced a major bleeding episode after a squint surgery was experimentally 
treated with a whole- blood transfusion and survived (2). Further advances in 
transfusion technology achieved during World War II, eased access of 
haemophiliac patients to blood or plasma transfusions, as a result life expectancy 
reached in average 39,7 years (5). 
*Blinded Manuscript
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 2 
Judith Poo in 1964 discovered that the cryoprecipitate fraction of plasma contained 
proportionally greater quantities of FVIII (4). The new product could be transported 
and administered by the patient himself reducing barriers to prompt therapy. 
Mortality rates, scholar and work abstention significantly dropped and the 
haemophilic patients reached an average life expectancy of 60 years (1). By 1970's 
medium purity concentrates were authorized for commercialization. At the same 
time Nilsson and Ahlberg in Sweden pioneered the regular administration of FVIII 
in a prophylactic, these new circumstances raised life expectancy again, this time 
to up to 68 years of age (1,4). Enhanced by the availability of new therapeutic 
options, the easier methods of administration and the raising life expectancy, 
plasma demand steadily grew throughout the following years. Solely in the U.S. 
there was a pool of approximately 20.000 donors, most of them poor people getting 
paid for this activity. Even though there was a boom in the rates of blood 
donations, the screening process was far from systematic and some donors were 
considered to be at greater risk of transmissible diseases than the general 
population. Infusion and transfusion of plasma derivatives were not safe and 
complications started to appear soon after (5). 
In 1982 the first US haemophilic patient was reported as being infected with the 
Human Immunodeficiency Virus (HIV) (6); this new discovery raised concern and 
the led to further report of additional cases; HIV reached incidence rates of 60 
cases per million in 1990 in the US and 1 case in every 7 people in the UK among 
haemophilic population (6, 7). HIV accounted for a quarter of all causes of death 
during the 1990's in Netherlands (8, 9).  It has been estimated that 80% of all 
deaths from the Acquired Immunodeficiency Syndrome (AIDS) occurred before 
1995. It was only after the mid 1990's with the introduction of antiretroviral therapy 
(ARVT) that HIV related mortality in the haemophilic patients dropped (10), a 
Canadian study that monitored all causes of death in haemophilic patients between 
1982- 2003 (n= 2427) showed a reduction in mortality rates due to HIV from 74,6% 
during 1982- 1997 to 42,9% after ARVT introduction (6,11). By 1992 an estimated 
of 60% of the US haemophilic patients, and 80% of all patients ever treated with 
clotting factor concentrates were already infected with hepatitis C (12, 13).  
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During the mid-1980s the genetic sequence of FVIII gene was achieved to produce 
recombinant factor VIII (rFVIII)(14).  The new rFVIII did not require any type of 
plasma for its production, first patient treated was reported in 1987. Since 1985 
there have been no reports of viral transmission linked to the use of rFVIII in the 
developed world; virally safe products for hepatitis C are also available from 1992 
onwards (8, 13). With the development of this new replacement alternative the 
prognosis of haemophilia has dramatically changed; for instance in UK life 
expectancy for a mild to moderate haemophiliac rounds 70 years of age, very close 
to that for general local population, whereas for severe cases of haemophilia it is 
estimated to be at least 15 years less, similar findings have been reported for the 
Dutch haemophilic population (15).  
 
From the 1990s onwards risk of blood borne infections has been controlled with the 
extended use of recombinant replacement therapy, as well as with the introduction 
of more sensitive immunoassays for the serological markers associated with 
transfusion-transmitted viruses (TTVs). Main concerns in the haemophiliac 
community have changed, the development of inhibitors (a neutralizing 
immunoglobulin directly acting against factor VIII) is a frequent and serious 
complication that has captured researchers´ attention; hence there is academic 
interest on comparing different treatment options and their association with the 
emergence of these antibodies. From 2000 onwards the main concerns of 
researchers have been placed around the future costs and cost- effectiveness of 
long term treatment. Equity considerations are relevant as well, and alternative 
options for less affluent countries are under the scope of further research. 
 
Most of the scientific evidence on haemophilia A treatment comes from High 
Income Countries (HIC) (16), and although all the promising findings from new 
technological developments, it is not yet clear if risks or complications will raise in 
the near future for rFVIII users, or if the incremental costs derived from higher 
survival rates and costly treatment options will lead to unsustainable health 
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systems. The question if there are any other therapeutic alternatives for less 
affluent countries becomes relevant.  
This systematic review was undertaken to assess the evidence of different 
treatment options for haemophilia A, with special interest on how the major 
improvements over the last four decades have influenced the natural course of 
disease.  Special attention was placed on the type and quality of published data, 
and results are presented decade by decade throughout these forty years.  
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Methods: 
Publications considering the clinical effectiveness of different treatment options for 
haemophilia A (including at least one of these dimensions: bleeding episodes, 
frequency and importance of adverse effects, potential complications, quality of life, 
cost - effectiveness, and cost – utility and the development of inhibitors) were 
sought.  The following search terms were used throughout the search: [hemophilia 
A], [coagulation disorder], [clotting factor disorder], [clotting factor deficiency], 
[clotting factor disease], [treat*], [therap*], [manage*], [current], [updat*], [novel], 
[classic*], [traditional], [conventional], [health outcome],  [Impact],  [effect*],  [quality 
of life] taking into account headings and sub- headings.  
Possible studies of interest were sought from Medline, Embase, health economics 
and health technology assessment database, Ovid, ACP Journal Club, Cochrane 
Controlled Trials Register, The Cochrane Database of Systematic Reviews, 
Econlit. The Medline strategy is listed in Appendix 1. Three independent 
researchers ran the search, a fourth researcher acted as peer reviewer and 
provided additional sources of data from relevant published and grey literature 
sources.  
Inclusion criteria were: Systematic reviews of literature and meta- analysis, 
randomized controlled trials, cohorts, case and control study, case study, economic 
evaluations, review articles. Complete articles published in English from 1970 
onwards were sought. 1970 was set as relevant date since it was the time of 
starting use of plasma- derived clotting factors; studies of patients at all ages were 
included, only those publications assessing treatment for haemophilia A 
(regardless of severity, complications, type of treatment, age of diagnosis or 
treatment initiation) were considered.  Publications that described and/ or 
compared the classic/ conventional vs. current/ updated therapeutic strategies for 
haemophilia A were included.  
Exclusion criteria were: publications considering patients with coagulation 
disorders different than haemophilia A, publications addressing patients with 
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 6 
acquired haemophilia A (due to the clinical differences of presentation, natural 
course of disease, co-morbidities, and therapeutic response to usual treatment). 
Quality control and assessment of data included, extraction and synthesis by three 
different reviewers with the aim to reduce potential bias, the PRISMA workflow was 
used to systematically assess papers retrieved and to control for duplication and 
eligibility criteria. Given the heterogeneity of studies and evidence a detailed 
qualitative quality assessment matrix was constructed considering date of 
publication, period of analysis, type of study. Studies were ranked based on 
quality. RCTs, Meta- analyses, Systematic reviews, Cohort studies fulfilling all 
criteria for internal validity according to the type of study were scored as ++;  when 
findings came from case and control studies, case studies, observational studies  
fulfilling all criteria for internal validity according to the type of study,  or from RCTs, 
Meta- analyses, Systematic reviews, Cohort studies partially fulfilling criteria for 
internal validity, they were rank as +; evidence from the grey literature or case- 
control studies, case studies, observational studies  that did not fulfil any criterion 
for internal validity were scored  0. The table of evidence and the grading criteria is 
depicted in Appendix 2.  
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RESULTS 
Stock of available evidence: 
A total of 1755 articles were retrieved from the search as potentially relevant 
references; 7 records were suggested by an expert in haemophilia to be added to 
the total number of possible articles to be analysed; 1749 publications were 
recognized after controlling for duplicates; after abstract scanning a total of 1607 
articles were excluded because they did not specifically addressed the main topic 
of research (only subjects with haemophilia A); after scoping for references that 
described and/or compared different treatment options for haemophilia A, 142 
relevant references we obtained;  50 full text articles were screened for eligibility 
criteria and  12 full text were excluded with reasons, a total of 38 publications were 
finally included in this qualitative analysis (See Figure 1). Available evidence by 
decade, by treatment focus, and by type and quality of publication are presented 
below. A summary of evidence is provided at the last part of the results section.  
 
 
Insert Figure 1. Approximately right here. 
 
 
Major findings by decade: 
 
The 1970’s: 
No reference published during the period between 1970- 1979 was retrieved from 
our search, notwithstanding we found five publications that included in their 
analyses the changes, improvements and concerns related with the different 
options of treatment for haemophilia A during this period of time. Four narrative 
reviews and one cohort study referred to this decade, the main subjects of these 
articles included: the evolution of treatment of haemophilia throughout history, 
discussion of therapeutic options at that time, the perceived risks associated with 
the use of blood products during the 1970’s, the availability and possible benefits of 
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 8 
home- based blood transfusions, and the improvement of quality of life derived 
from treatment. The cohort study reported the risk of inhibitors development in a 
population of UK patients  followed between 1977 and 1999, suggesting an inverse 
association between early exposure to exogenous clotting factor  and the 
appearance of inhibitors in these patients during the 1970’s. 
 
The 1980’s: 
Despite no articles were found as published during this; four references account for 
data from this period of time, they are all narrative reviews of the treatment options 
for haemophilia during this decade. The major emerging concern was the onset of 
communicable diseases transmitted via transfusion products used for the treatment 
of haemophilia A,  all the publications depicted the association between standard 
treatment (cryoprecipitate) and the development of contagious diseases like AIDS, 
Hepatitis C and Hepatitis  non A non C, claimed for the need of safer screening in 
the manufacturing process of products for haemophilia acre, and urged for 
research and development for a new and safer blood- derived products. The first 
case report of the clinical efficacy (case report with two patients) of rFVIII, fostered 
the industrial production of rFVIII becoming publicly available in 1989.  
 
The 1990’s: 
We found three publications from this decade.  One cohort study described the 
relationship between FVIII replacement characteristics and inhibitor development in 
previously untreated patients between 1990-2000; this study concluded that 
regular prophylaxis was associated with a 60% lower risk than on- demand 
treatment (RR, 0.4; CI, 0.2-0.8) for developing inhibitors, and that inhibitor 
occurrence appeared to be associated with the age of first exposure to treatment, 
decreasing from 41% for those treated within the first month of age to 18% in those 
treated after 18 months of age; one narrative review described two different clinical 
approaches on minimizing or delaying inhibitor development,  and a report from the 
grey literature that presented rFVIII, as new therapeutic alternative for children with 
severe haemophilia A. The development of recombinant products and the 
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 9 
appearance of inhibitors became major topics of research that led to academic 
publications comparing the different available options. 
 
The 2000’s: 
The stock of knowledge about haemophilia exponentially increased during this 
decade, 32 publications were found in our search (80% of all references retrieved), 
some of these articles accounted in their period of analysis for previous decades. 
We sought two systematic reviews from this period of time about the cost- 
effectiveness of treatment options in patient with inhibitors, and on the efficacy of 
the immune tolerance treatment to control for it.  
 
Three cohort studies were also found comparing different treatment options, the 
type of factor VIII used (FVIII vs rFVIII), and the timeframe exposure and the 
development of inhibitors; additionally twelve review articles, two randomized 
clinical trials, one case and control study, one case study and one economic 
evaluation were retrieved and appraised from this period, the dominant research 
topic was the identification of risk factors for inhibitors development, and also 
alternative comparison of different treatment options in patients with inhibitors, the 
advantages of prophylaxis (primary and secondary) over on- demand therapy, the 
comparison between alternative primary prophylaxis regimes in terms of 
haemophilic arthritis prevention, the association between the number of bleeding 
episodes and quality of life, the cost- effectiveness and the availability of alternative 
regimes in developed and developing countries. 
 
2010 onwards: 
 
Five review articles and one systematic review have been published since 2010 up 
to date (23rd September 2011), this publications discussed the role of prophylaxis 
in the prevention of haemarthrosis in children with haemophilia, the sensed need to 
establish a gold standard for primary prophylaxis, the alternative current options to 
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 10 
treat acute bleeding events in patients with inhibitors, and the available options to 
treat mild haemophilia A. 
 
The report of evolving treatment strategies: 
 
None of the publications retrieved through the search was dedicated to on- 
demand therapy entirely, nevertheless three articles (narrative reviews), described 
the use of this approach during the 1970’s and early 1980’s, right before the 
inception of recombinant technology, and before prophylaxis became current 
practice, access barriers to prompt treatment in hospital settings are mentioned as 
main disadvantages of this therapeutic scheme, delays between the initiation 
treatment and the subsequent repercussions on the quality of life of patients are 
discussed in a few of these articles; one case and control study unveiled the 
differences in the quality of life between patients treated with on- demand vs. those 
treated with primary prophylaxis in Europe favouring prophylaxis  in terms of 
physical functioning, less role limitations, bodily pain, general health, vitality, social 
functioning, emotional role limitations, and overall mental health. 
 
Three quarter of our reviewed articles primary focused on primary prophylaxis (a 
total of thirteen articles were retrieved, seven narrative reviews, one cohort study, 
one case and control study, one case study, one economic evaluation and two 
reports from international conferences from the world federation of haemophilia 
classified as grey literature). The main topics discussed by these papers were, the 
need to decide on an international standard for  primary and secondary 
prophylaxis, the optimal age for initiation and duration of prophylactic treatment, 
the advantages of prophylaxis in terms of prevention of haemarthrosis and 
disability in the long term, and subsequently the positive impact of this approach on 
the overall quality of life when compared  with on- demand therapy; the 
determinants and barriers to comply with treatment as well as the comparative 
cost- effectiveness of prophylaxis and the possible financial  limitations for its 
instauration  in developing countries. 
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Just a limited number of articles were related to secondary prophylaxis, we found 
two randomized clinical trials (RCTs) and one review article linked with this scheme 
of treatment. One RCT enrolled 38 male patients with a high baseline bleeding 
frequency (mean ‡ 4 bleeds per month) in a pre- prophylaxis stage for a period of 
three months. Twenty-two patients were randomized to receive daily rFVIIa 
prophylaxis with either 90 or 270 IU per Kg during a period of 3 months, followed 
by a 3-month post prophylaxis period.  Bleeding frequency was reduced by 45% 
and 59% during prophylaxis with 90 and 270 IU per Kg, respectively (P < 0.0001), 
Patients reported significantly fewer hospital admissions and days absent from 
work/school during prophylaxis compared to the pre-prophylaxis period. The 
second RCT examined the role of secondary prophylaxis with rFVII in quality of life 
improvement; rFVIIa prophylaxis significantly reduced bleeding frequency vs. prior 
on-demand therapy (P < 0.0001). Hospital admissions (5.9% vs. 13.5%; p= 
0.0026) and school/work absenteeism (16.7% vs. 38.7%; p= 0.0127) were reduced 
during prophylaxis, and tended to remain during post- prophylaxis. The review 
article referred to the benefits of secondary prophylaxis on joint damage 
prevention, functional capacity and quality of life, suggesting it to be considered as 
an alternative therapeutic option for patients that cannot or are not willing to 
receive primary prophylaxis. 
 
Eight publications were focused on haemophilia type A with inhibitors treatment. 
Two were systematic reviews; five were reviews articles and one a case study.  
One of the systematic reviews and one review article summarised the best 
available evidence on the clinical effectiveness to treat acute bleeding events in 
haemophilia A patients with inhibitors, comparing high-doses of FVIII, Porcine FVIII 
and Activated Prothrombin Complex Concentrates (APCC) with the final outcome 
(control of spontaneous bleeding episodes and haemorrhages secondary to 
surgery); one systematic review and one narrative review discussed the efficacy, 
safety and effectiveness of the products currently available for immune tolerance 
induction; one review article described the efficacy and effectiveness of rFVII as a 
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new option to  treat patients with inhibitors in terms reducing inhibitor levels in the 
short and long term; One review article compared the efficacy of different drugs 
emphasising on the haemostatic effect of rFVIII and FEIBA, and the use of 
prophylaxis with rFVIIa (surgical- and non-surgical settings) and the associated 
reduction in the number of bleeding events and the improved quality of life. Finally 
one case study described the use of Rituximab in a single dose for 3 patients with 
high and low titter inhibitors, showing clinical improvement in terms of bleeding 
frequency and inhibitor levels 
 
Type of publications and quality of evidence level: 
 
A total of 38 articles were qualified, three of them were classified as systematic 
reviews (one ranked as middle quality and two as high quality of evidence). Only 2 
randomized clinical trials were retrieved in our search (one classified as high level 
of evidence and the second one combined with an economic study middle level). 
More than a half of the publications were review articles (total number of 21), and 
all of them were classified as middle quality of evidence. 5 cohort studies were 
obtained (all of them were ranked as high quality). Two case studies (ranked as 
middle level of quality of evidence). 3 economic evaluations retrieved (one was 
ranked as middle level and combined with a RCT, and the other two were ranked 
as high quality of evidence). 3 reports were retrieved from the grey literature, all of 
them scored as low quality of evidence.  
 
It was remarkable fining the lack of RCTs comparing different treatment options for 
severe haemophilia A, perhaps derived from the ethical limitations of 
randomization after prophylaxis proved to be clinically effective. During the 1970’s 
and 1980´s although very limited, narrative reviews and grey literature dominated 
the stock of knowledge with their subsequent prompt to bias. After the 1990’s the 
number of publications for haemophilia A have exponentially increased via reports 
from cohort studies, systematic reviews and a few number of randomized 
controlled trials. From the 2000 onwards quality of evidence has improved as well 
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as the number of cost- effectiveness and cost- utility analyses regarding this 
condition. 
 
Summary of findings on treatment: 
 
Over the last four decades management of patients with haemophilia A has 
experienced dramatic improvements, notwithstanding its ups and downs 
throughout history.  A wide range of therapeutic strategies have been developed 
since the 1970 decade.  On the one hand the conventional on- demand treatment, 
consisting of missing factor supply after the onset of a bleeding episode, is an early 
approach that despite an incredible improvement in life expectancy, accounted for 
poor quality of life outcomes; access barriers to hospital provision of clotting factor, 
and the subsequent joint damage from lack of prevention were pitfalls faced by 
clinicians and patients (4).  
 
In contrast, prophylaxis defined as a form of prevention has proven to be superior 
in preventing bleeding events, and their subsequent sequelae.  Although there are 
several prophylactic schemes a consensus meeting of experts held in London in 
2002, helped to define “primary prophylaxis” as a long-term continuous treatment 
(intent of treating 52 weeks per year up to adulthood receiving treatment at a 
minimum of 46 weeks per year), started before the age of 2 years and prior to any 
clinically evident joint bleeding or before the onset of joint damage irrespective of 
age (defined as having had no more than one joint bleed) (18). This prophylactic 
replacement of clotting factor has been recommended as the gold standard of care 
by the World Federation of Haemophilia (WFH) and the World Health Organization 
(WHO).  
 
Several studies retrieved from our search have demonstrated superior 
effectiveness of primary prophylaxis in the reduction of bleeding frequency, hence 
on preventing and reverting of haemophilic arthropathy vs. on- demand therapy. 
The US Joint Outcome Study (JOS), the first randomized clinical trial that 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
compared prophylaxis and on- demand therapy, included 65 young children (< 
than 30 months of age), who were randomized to receive prophylaxis vs. on- 
demand treatment  (infusions of 25 IU per Kg of FVIII every 2 days for prophylaxis 
vs. on- demand treatment three or more infusions of factor VIII, using at least 80 UI 
per Kg to treat articular bleeds), the annual mean incidence of bleeding episodes 
was much less in the prophylaxis group compared to the on- demand group (0.63 ± 
1.35 vs. 4.89 ± 3.57 respectively p < .001), in additional  93% of patients allocated 
in the prophylaxis group had normal joint indexes assessed by Magnetic 
Resonance Imaging (MRI), in contrast to 55% of patients treated on- demand (p = 
.006) (19).  These results were backed by a  prospective 10 year Italian trial 
(ESPRIT), which enrolled 40 patients younger than 7 years of age with negative 
clinical and radiological scores for joint damage; patients were randomized to be 
treated with recombinant factor VIII (rFVIII) 25 IU kg  three times a week or on- 
demand (25 IU kg) until complete healing, results indicated that prophylaxis is 
associated with significantly fewer breakthrough bleeds than on- demand treatment 
(0.24 vs. 1.30 bleeds per month, respectively; P < 0.001) (19- 21). A retrospective 
cohort analysis involving 156 Norwegian and Swedish patients suggested that 
patients who received prophylaxis required fewer total invasive procedures than 
those who received on- demand treatment (22). Less number of bleeding 
episodes, and life threatening haemorrhages under prophylaxis, should be 
associated with a much better joint status and a better quality of life. A European 
study assessing Health related Quality of Life (HR-QoL) applied the Short-Form 36 
(SF-36) which accounts for eight dimensions of HR-QoL to 1033 haemophiliac 
patients of 12 years of age with moderate to severe haemophilia, five of these eight 
dimensions were significantly higher in HIV negative patients receiving prophylactic 
therapy when compared to on- demand, these dimensions included, physical 
functioning, bodily pain and mental health (20, 23). 
 
According to the literature, besides the benefit of haemophilic arthropathy 
prevention from prophylaxis a marked reduction of intracranial haemorrhages, 
lower muscular-skeletal pain, lower rates of inpatient admissions and average of 
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stay, improved school and work attendance and improved academic achievement 
have been reported (18, 24). A starting age of treatment between 1 to 2 years of 
age could be associated with no risk at all of developing haemarthrosis under 
sustained treatment (18), a Dutch cohort study that evaluated the optimal age to 
start prophylaxis demonstrated that an early start resulted in complete prevention 
of joint damage for 70% of boys compared with 31% for boys who started 
prophylaxis after 3 or more bleeds.  
 
Approximately 10% of severe haemophiliacs do not bleed as frequently as would 
be expected from their circulating factor levels (24). The JOS study suggests that 
the occurrence of the first joint bleed rather than a specific age may represent a 
reasonable criterion for starting prophylaxis (21). After two decades of follow up, 
the radiological Pettersson joint score (a scoring system that increases based on 
radiological evidence of haemophilic joint damage) was 8% higher for every year 
prophylaxis was postponed after the first joint bleed, this data suggests that 
primary prophylaxis should be started at an early age but can be individualized 
based on the bleeding pattern of each individual (25).  
 
A consensus about the best prophylaxis protocol is still undetermined. Primary 
prophylaxis based on the Swedish protocol (also known as the high-dose Malmö 
protocol) involves the administration of 20– 40 Factor VIII UI per Kg three times a 
week, and is currently considered the gold standard of care. This protocol is  
recommended by the WFH, WHO, the UK Haemophilia Centre Doctors 
Organization and the Medical and Scientific Advisory Council of the US National 
Haemophilia Foundation as the optimal treatment until a cure is available (25, 26).  
Nevertheless there are several protocols available and still being used. The Dutch 
intermediate-dose prophylaxis protocol supplies  15–25  factor VIII IU per  Kg 
infused  two or three times a week and the subsequent prophylactic dose is 
adjusted based on spontaneous breakthrough bleeding into joints and not 
according to the subject body weight or trough levels of FVIII (25).  
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The Canadian approach was a dose-escalation scheme of primary prophylaxis 
started in 1997. In this prospective study, boys at ages 1 year to 2,5 years with 
severe haemophilia A, started on a once weekly infusion of FVIII (50 IU kg). If 
clinically significant bleeding into muscles and/or joints occurred, the frequency of 
FVIII infusion was increased to twice weekly (dose 30 IU kg); continuation of 
bleeding resulted in  escalation of the prophylaxis regimen up to 25 IU kg) on 
alternate days. Criteria for escalation included: ‡ 3 clinically determined bleeds into 
any one joint over a consecutive 3-month period; ‡ 4 significant soft tissue/joint 
bleeds over a consecutive 3-month period and ‡ 5 bleeds into any one joint while 
on the same dosage (step) of factor therapy over any period of time (25, 27, 28).  
 
Nonetheless all the possible options, the Swedish high-dose prophylaxis regimen 
is associated with a significantly lower rate of joint bleeding in comparison with the 
Dutch intermediate-dose regime; FVIII consumption and costs were approximately 
twofold higher for the former scheme. After at least after 20 years of follow-up, the 
extent of haemophilic arthropathy measured by a radiologic scale is similar for 
these two prophylaxis regimens. In the Canadian study one-third of patients 
appeared to be successfully maintained on a once per week prophylaxis regimen 
for a considerable period of time without the need for escalation. This suggests that 
rapid progression in treatment, as employed in the Swedish regimen may be 
unnecessary in a small proportion of patients. Yet in the Canadian study several 
patients developed target joints prior to the escalation of therapy. Furthermore, 
despite the absence of life-threatening bleeds seen in the Canadian study, there is 
a concern that with once weekly prophylaxis these patients remain at risk of 
serious and even life-threatening bleeds for most of the time (29).  Nevertheless 
this approach might be less costly while infusing less factor concentrate than with a 
traditional prophylaxis regimen, and also may reduce the need for a central venous 
catheter (CVC), and hence its complications (infection or thrombosis). A problem 
with this approach is that there are currently no standard criteria for determining 
unacceptable bleeds. Moreover, the long-term joint outcome of this approach and 
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its protective effect against other serious bleeds is not known, because of the 
infrequent once-weekly dosing in many patients (26). 
 
There was no literature found in our search that supported the interruption of 
prophylaxis in the adulthood, institutions like the WFH, The US national foundation 
of haemophilia and the WHO recommend continuing prophylaxis in the adulthood, 
because adults remain at risk of developing joint or other kind of bleedings. A 
follow-up Dutch and Danish study showed that 28 out of 80 (35%) severe 
haemophiliacs permanently discontinued prophylaxis in early adulthood. These 
patients experienced on average 3.2 joint bleeds annually over the 3 years after 
discontinuing prophylaxis. Patients who remained on prophylaxis experienced on 
average 1.8 joint bleeds annually during the same time period (19, 24).  
Paradoxically, limited evidence suggests that those patients who permanently 
discontinued prophylaxis tended to have a milder bleeding pattern than those who 
continued prophylaxis (27). According to one reference counselling for adolescents 
and young adults about the consequences of abandoning primary prophylaxis is 
essential to prevent complications (30). 
 
Secondary prophylaxis is defined as a long-term continuous treatment not fulfilling 
the criteria for primary prophylaxis (4, 18), and has the primary aim to reduce and 
arrest joint bleeding and to halt the progression of joint destruction. It is intended to 
reduce the risk of other serious haemorrhage, such as intracranial bleeds (31). In a 
study of 21 patients receiving secondary prophylaxis at three different ages (1–2, 
3–6 and >6 years), Kreuz et al found that although the number of joint bleeds 
decreased significantly during prophylaxis in the two older groups, radiologic and 
orthopaedic scores still deteriorated for those who reported more than five joint 
bleeds before the initiation of prophylaxis, suggesting that once joint damage had 
started, further joint deterioration could not be prevented by the initiation of 
prophylactic therapy (26), even though secondary prophylaxis cannot reverse the 
changes of chronic arthropathy, it may be beneficial by reducing frequency of 
bleeding, hospital admissions and lost days from school or work, and by 
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decreasing damage progression. Patients treated with secondary prophylaxis had 
a decreased number of joint bleeding episodes at the expense of higher clotting 
factor concentrate consumption (4). A growing consensus among haemophilia 
specialists is that an individualized protocol for each patient based on the bleeding 
pattern and manifestations of the disease should guide decisions regarding the 
prophylaxis regimen. Recent studies examining delayed initiation of secondary 
prophylaxis are encouraging because they demonstrated that even delayed 
prophylaxis can reduce the frequency of joint haemorrhages, lessen chronic joint 
pain, enhance quality of life and, and when combined with aggressive 
physiotherapy, may improve physical function and the radiographic appearance of 
target joints (31). 
 
There are several barriers for the use and the adherence to prophylaxis, a study of 
patients at the Louisiana Comprehensive Haemophilia Care Center found lower 
rates of adherence among patients receiving high-intensity treatment regimens 
(32), of the 18 patients in the study’s high-intensity group, only 3 (17%) had high 
adherence (20). Some of the barriers that influence the adoption of and adherence 
to prophylaxis are the cost and availability of clotting factors (accounting for about 
80 – 90% of the total cost of treatment), prohibitive particularly for less affluent 
communities (19).  Six additional identified barriers to prophylaxis were (as 
indicated by 30% of patients families in a study of 52 patients in the Mountain 
States Regional Hemophilia and Thrombosis Center- Aurora, CO, USA): the 
greater amount of venous access devices (required for long term treatments- three 
folding on- demand regimens); the complications associated with those devices 
(including infections and thrombosis);  the need for therapy as perceived by the 
patient; immediate social and family needs; parents inability to gain cooperation 
from their young children, and specially the time required for prophylactic infusions. 
These data suggest that products with higher dosages, longer half-lives or more 
convenient mechanisms of infusion could improve adherence in patients with 
haemophilia (20).  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
Notwithstanding the clear clinical effectiveness of prophylaxis, it also results more 
costly with respect to on- demand treatment, Miners et al calculated an Incremental 
Cost Effectiveness Ratio- ICER well above the  £30 000 per QALY gained 
threshold, when compared to on- demand therapy, a recent review of calculations 
(adjusting clotting factor price, and long term effect of treatment) by the same 
author estimated it is getting closer to being considered cost- effective (according 
to NICE thresholds in the UK) (33). 
 
Despite the consistent evidence about the benefits of prophylactic therapy, a 
recent global survey of 147 haemophilia treatment centres (HTCs) throughout the 
world showed that about a half of all patients with severe haemophilia A (54%) still 
receive on-demand treatment, and only 19% are provided primary prophylaxis (20). 
Even in High Income Countries- HIC, prophylaxis coverage is not universal, in the 
US only 50% of severe haemophiliacs type A are treated under the gold standard 
approach, this compared with 77% of patients in Canada (Universal Data 
Collection (UDC) (31). The situation is much worse in emerging countries in which 
the development of effective healthcare programs for haemophiliacs is still limited, 
and where limited resources, the short availability of VIII factor concentrates means 
an important barrier to provide prophylactic regimens.  
 
   
After  the improvement in safety of human derived blood products, the 
development of recombinant factor concentrates and the subsequent reduction in 
morbidity and mortality by blood- transmitted  diseases, the development of 
inhibitors (neutralizing antibody direct against FVIII), became the major concern of 
in haemophilia care. In patients who develop inhibitors, the location and frequency 
of bleeding episodes is usually similar to those who did not develop alloantibodies, 
however, the prophylactic treatment is unfeasible and the treatment of acute 
episodes is complicated, since inhibitors increase the rate of FVIII neutralization, 
by partial or total reduction of its clinical activity (35, 36).  Most centres consider 
>0.6 Bethesda units (BU) as a positive result for having an inhibitor.  
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Several factors have been related to the development of inhibitors, the most 
strongly associated is a type of genetic mutation of FVIII, as well as the type of 
Human Leucocitary Antigen (HLA) and the polymorphisms in the genes codified for 
cytokines (African or Hispanic background) of each individual (37), as well as the 
type of replacement therapy used and the age of starting up. In a study by 
Santagostino et al, 25 out of 108 children with haemophilia received prophylaxis 
and had a lower inhibitor risk than those treated on- demand (adjusted OR 0.2; CI: 
0.06–0.9), suggesting a protective effect of prophylaxis from inhibitor development. 
A second study (Concerted Action on Neutralizing Antibodies in severe 
haemophilia A- CANAL), 87 out of 386 (24%) previously untreated patients 
receiving treatment for at least 50 consecutive days developed clinically relevant 
inhibitors. Regular prophylaxis was associated with a 60% lower risk than on- 
demand treatment (RR 0.4; CI, 0.2-0.8). Factors associated with an increased risk 
of developing inhibitors included a high-intensity treatment at first exposure to FVIII 
and high cumulative dose of FVIII during five consecutive treatment days. The 
incidence of inhibitors appeared to be associated with age at first treatment, 
decreasing from 41% for those treated within the first month of age to 18% in those 
treated after 18 months (36, 38). 
 
The CANAL study also reported the association of FVIII product type (i.e. plasma-
derived vs. recombinant) and switching between FVIII products with the risk of 
developing inhibitor and concluded that neither plasma-derived FVIII products were 
associated with a lower inhibitor risk than recombinant FVIII products, nor the 
switching between FVIII product brands increased the inhibitor risk. In contrast a 
cohort that evaluated 62 patients treated with the same brand of high-purity 
plasma-derived FVIII (pFVIII) containing Von Willebrand factor (VWF) and 86 
patients treated with full-length recombinant FVIII (rFVIII) concluded that the risk of 
inhibitor development was higher in patients treated with rFVIII than in patients 
treated with pFVIII, regardless of other risk factors (F8 genotype; non-white origin; 
history of inhibitors in patients with a family history of haemophilia; age at first FVIII 
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infusion). The adjusted relative risk (RR) for inhibitor development with rFVIII 
versus pFVIII was 2.4 (17, 39).  
 
In a retrospective a cohort study by Chalmers et al. assessed the incidence of 
inhibitors in three hundred and forty-eight children with severe haemophilia A. They 
found that 68 out of 348 (20%) developed inhibitors (10% corresponding to high 
titter inhibitors). The incidence with regards to the age of initial FVIII exposure was:  
26% in patients younger than 1 month, 25% in patient between 1- 6 months, 21% 
between 6- 12 months, 20% in 12- 18 months and 9% in patients older than 18 
months of age. A significant difference in inhibitor development and age at first 
exposure across all age groups was found (p= 0.018), but no significant difference 
was observed in children treated at different time points during the first year of life 
(p= 0.44). In this study, exposure to FVIII during the neonatal period was not 
associated with a higher incidence of inhibitors compared with those treated later 
during the first year of life. Mortality associated with the development of inhibitors 
has change through years, in severe haemophiliacs without HIV, inhibitor 
development doubled mortality during 1977–92 in the UK, but during 1993–99 
mortality was identical with and without inhibitors. In severe haemophiliacs without 
HIV but with inhibitors, mortality from causes involving bleeding decreased during 
1977–99 (p= 0.001) as did mortality involving intracranial haemorrhage (p= 0.007), 
these results do not appear to be related with the type of treatment for haemophilia 
or the treatment for the inhibitors. (40).  
 
Currently there is an increasing range of options to treat haemophilic patients with 
inhibitors, these include: high doses of human factor VIII (FVIII), high purity factor 
VIII (pFVIII):, By passing agents: (Prothrombin Complex Concentrates- PCCs), 
Activated Prothrombin Complex concentrate (aPCCs)], Factor VIII bypassing 
agent- FEIBA, Recombinant Factor VIIa (rFVIIa),  and Immune tolerance therapy 
these are further described in Appendix 3. 
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Conclusions: 
 
Notwithstanding the ups and downs in the haemophilia care history, a sustained 
success has emerged from the larger availability of safer plasma-derived and 
recombinant replacement products from the late 1980s onwards, especially in the 
develop world.  Improvement in administration techniques and dosing regimens, 
the introduction of home treatment, a progressive shift from on-demand treatment 
to prophylaxis, the onset of antibodies inactivating the infused clotting factor 
(inhibitors), and the further development of options to treat and possibly eradicate 
them, account for this recent successful story.  
 
The development of recombinant factor VIII potentially eliminates the risk of 
infectious disease transmission, nevertheless a theoretical risk of transmitting 
emerging non-viral pathogens such as the prion responsible for variant of the 
Creutzfeldt Jakob disease (vCJD) still remains. With each new challenge a new 
successful solution has emerged, all these developments have resulted in 
increased life expectancy and health-related quality of life for haemophilic patients, 
henceforth an illness with a different spectrum has emerged.  
 
Literature has largely demonstrated the superior clinical effectiveness of 
prophylaxis when compared with on- demand therapy. Data from the WFH and 
WHO proved that prophylaxis is still distant to become universal, and for those 
countries with the lowest per capita gross national product (GNP) haemophilia 
healthcare is either inadequate, or there is no care at all. The impact of these 
deficiencies in haemophilic patients’ life expectancy and quality of life are expected 
to be substantial. Currently, in emerging countries with lower incomes, the 
implementation of prophylactic treatment programs seems unachievable, 
especially with rFVIII. In this order of ideas, it remains as an important challenge to 
improve access to prophylaxis in emerging communities.  
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Further data and long-term studies are needed to determine whether a group of 
patients who can safely discontinue prophylaxis can be identified, hence procuring 
long term financial sustainability of health systems; additional robust cost- 
effectiveness studies comparing the current on- demand practice in developing 
countries with alternative prophylaxis regimes are also needed. Finally studies 
comparing different immune tolerance protocols will serve to determinate the best 
options in terms of efficacy, safety and cost- effectiveness for those societies able 
to afford it. 
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Figure 1. Prisma flow diagram systematic review on hemophilia A. 
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